Type 2 Diabetes in Patients with G6PD Deficiency

This cohort study investigated the impact of glucose 6 phosphate dehydrogenase (G6PD) deficiency on diabetes management and outcomes. Comparing 3,913 patients with G6PD deficiency to 19,565 matched controls, the study found that glycated hemoglobin levels significantly underestimated glucose levels in G6PD deficient patients (4.79% vs. 5.50%, P<0.001). These patients were less likely to receive GLP 1 receptor agonists (adjusted HR 0.77) or SGLT2 inhibitors (adjusted HR 0.78) and had higher incidences of severe kidney disease (HR 1.51), ischemic heart disease (HR 1.33), and neuropathy (HR 1.33). The findings highlight the unreliability of glycated hemoglobin for diabetes diagnosis in G6PD deficient populations and underscore disparities in treatment access and outcomes.

This cohort study investigated the impact of glucose 6 phosphate dehydrogenase (G6PD) deficiency on diabetes management and outcomes. Comparing 3,913 patients with G6PD deficiency to 19,565 matched controls, the study found that glycated hemoglobin levels significantly underestimated glucose levels in G6PD deficient patients (4.79% vs. 5.50%, P<0.001). These patients were less likely to receive GLP 1 receptor agonists (adjusted HR 0.77) or SGLT2 inhibitors (adjusted HR 0.78) and had higher incidences of severe kidney disease (HR 1.51), ischemic heart disease (HR 1.33), and neuropathy (HR 1.33). The findings highlight the unreliability of glycated hemoglobin for diabetes diagnosis in G6PD deficient populations and underscore disparities in treatment access and outcomes.